SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.87
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sigma Healthcare is a retail pharmacy franchisor and full-line pharmaceutical wholesaler and distributor. Following its 2025 merger with Chemist Warehouse, its major pharmacy brands include Chemist Warehouse, Amcal and Discount Drug Stores.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.79

04 Nov
2026

-0.020

OPEN

$2.85

-0.71%

HIGH

$2.87

20,977,544

LOW

$2.78

TARGET
$3.12 11.8% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP . SK1 .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 6.2 7.3 xxx
DPS (cps) xxx 4.0 4.7 xxx
EPS Growth xxx 21.9% 17.8% xxx
DPS Growth xxx 100.0% 16.5% xxx
PE Ratio xxx N/A 38.8 xxx
Dividend Yield xxx N/A 1.7% xxx
Div Pay Ratio(%) xxx 64.8% 64.1% xxx

Dividend yield today if purchased 3 years ago: 5.97%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.42

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/09 - ex-div 2.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx6.2
DPS All xxxxxxxxxxxxxxx4.0
Sales/Revenue xxxxxxxxxxxxxxx10,835.0 M
Book Value Per Share xxxxxxxxxxxxxxx43.4
Net Operating Cash Flow xxxxxxxxxxxxxxx575.6 M
Net Profit Margin xxxxxxxxxxxxxxx6.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx14.67 %
Return on Invested Capital xxxxxxxxxxxxxxx10.62 %
Return on Assets xxxxxxxxxxxxxxx7.86 %
Return on Equity xxxxxxxxxxxxxxx14.67 %
Return on Total Capital xxxxxxxxxxxxxxx14.52 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx140.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx208 M
Long Term Debt xxxxxxxxxxxxxxx1,813 M
Total Debt xxxxxxxxxxxxxxx2,021 M
Goodwill - Gross xxxxxxxxxxxxxxx3,626 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx131 M
Price To Book Value xxxxxxxxxxxxxxx6.33

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx56.7 M
Capex % of Sales xxxxxxxxxxxxxxx0.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx8,878 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx959 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx114 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

22/10/2026

1

Buy

$3.20

14.70%

Post Sigma Healthcare's AGM trading update, Ord Minnett trims the target price to $3.20 from $3.40 and retains a Buy rating.

The 1H27 year-to-date Chemist Warehouse (CW) sales rose 12% y/y in Australia and met expectations with international CW sales up 30% y/y which was better than anticipated and ahead of forecasts.

The retailer has continued to show "resilience" despite some softness in more of the discretionary segments like fragrances and some vitamins.

Management expect to roll out 14-plus new stores for CW Australia and 19-plus international stores in 1H27 as well as 42-plus Amcal and DDS stores.

The broker continues to see structural tailwinds from GLP-1s and oral formulations coming to market in 2H27.

FORECAST
Ord Minnett forecasts a full year FY27 dividend of 4.40 cents and EPS of 7.40 cents.
Ord Minnett forecasts a full year FY28 dividend of 5.10 cents and EPS of 8.60 cents.

Bell Potter

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

23/10/2026

1

Buy

$3.50

25.45%

Jarden maintains a Buy rating for Sigma Healthcare with its target price decreased to $3.50 from $3.60 following an Annual General Meeting update featuring total sales growth of 12.1%.

Australian Chemist Warehouse like-for-like sales grew 9.8% year-on-year, falling slightly below expectations due to softer discretionary fragrance and vitamin purchases ahead of major cyber sales events.

International operations performed strongly, with sales climbing 15.8% year-on-year alongside preparations for the first United Kingdom store launch in late 2026.

The analyst lowers near-term earnings estimates by -1% to -2% to reflect softer second-quarter Australian like-for-like sales trends.

Despite these revisions, Jarden sees significant medium-term margin upside driven by network optimisation, retail media expansion, and the potential third-quarter rollout of oral GLP-1 treatments.

FORECAST
Jarden forecasts a full year FY27 dividend of 4.60 cents and EPS of 7.50 cents.
Jarden forecasts a full year FY28 dividend of 6.10 cents and EPS of 8.70 cents.
Access Extra Coverage Research History >

SIG STOCK CHART

FNArena News on SIG

1
Sigma’s Growth Prescription Extends Offshore

Oct 27 2026 - Australia
2
Weekly Ratings, Targets, Forecast Changes – 23-10-26

Oct 26 2026 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Oct 23, 2026

Oct 23 2026 - Daily Market Reports
4
Rudi’s View: Quality At Home, Value Abroad

Oct 22 2026 - Rudi's View
5
Rudi’s View: Lower Bond Yields & Other Catalysts

Oct 21 2026 - Rudi's View

Latest Health & Nutrition News

1
Sigma’s Growth Prescription Extends Offshore

Oct 27 2026 - Australia
2
Chemist Warehouse A Winner For Sigma Healthcare

Aug 31 2026 - Australia
3
The Defensive Proposition Of Sigma Healthcare

Mar 30 2026 - Australia
4
Sigma Healthcare’s Four Pillars Of Growth

Aug 29 2025 - Australia
5
Sigma Healthcare: Synergies, Margins In Focus

Jun 19 2025 - Australia
6
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
7
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
8
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
9
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
10
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia